{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:31:13Z","timestamp":1787859073924,"version":"build-2784847793"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T00:00:00Z","timestamp":1401148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Anti\u2010PM\/Scl autoantibodies are found in polymyositis, dermatomyositis, systemic sclerosis (SSc), and systemic autoimmune disease overlap syndromes. PM\u20101\u03b1 is a major epitope of the PM\/Scl complex, and antibodies against PM\u20101\u03b1 can be detected using a validated enzyme\u2010linked immunosorbent assay (ELISA). This study was undertaken to determine the prevalence and identify the clinical correlates of anti\u2013PM\u20101\u03b1 antibodies in a large cohort of patients with SSc.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum samples were obtained from 763 patients with SSc enrolled in a multicenter Canadian cohort. The sera were analyzed by ELISA for the presence of antibodies against PM\u20101\u03b1. Associations between the presence of anti\u2013PM\u20101\u03b1 antibodies and demographic, clinical, and other serologic manifestations of SSc were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Anti\u2013PM\u20101\u03b1 antibodies were present in 55 patients with SSc (7.2%), of whom almost 50% (26 of 55; 3.4% of the overall cohort) had no other SSc\u2010specific antibodies, namely anticentromere, anti\u2013topoisomerase I, and anti\u2013RNA polymerase III. Features positively associated with the presence of anti\u2013PM\u20101\u03b1 antibodies included younger age at disease onset, skeletal muscle involvement, calcinosis, inflammatory arthritis, and overlap disease. Interstitial lung disease was less frequent and there were fewer gastrointestinal symptoms present in patients with anti\u2013PM\u20101\u03b1 antibodies compared to patients without these antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anti\u2013PM\u20101\u03b1 antibodies are relatively common in SSc and are associated with a distinct clinical phenotype, consistent with that described in association with other anti\u2010PM\/Scl autoantibodies. Although anti\u2013PM\u20101\u03b1 antibodies are not exclusive of other SSc\u2010specific antibodies, they can be present in the absence thereof. Thus, anti\u2013PM\u20101\u03b1 antibodies may have considerable diagnostic and prognostic relevance in SSc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.38428","type":"journal-article","created":{"date-parts":[[2014,2,27]],"date-time":"2014-02-27T10:57:12Z","timestamp":1393498632000},"page":"1608-1615","source":"Crossref","is-referenced-by-count":93,"title":["Clinical and Serologic Correlates of Anti\u2010PM\/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients"],"prefix":"10.1002","volume":"66","author":[{"given":"Julie","family":"D'Aoust","sequence":"first","affiliation":[{"name":"McGill University, Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[{"name":"McGill University and Jewish General Hospital Montreal, Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Tatibouet","sequence":"additional","affiliation":[{"name":"Jewish General Hospital Montreal, Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wick","sequence":"additional","affiliation":[{"name":"University of Calgary Calgary, Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Canadian Scleroderma Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mahler","sequence":"additional","affiliation":[{"name":"Inova Diagnostics, Inc. San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Baron","sequence":"additional","affiliation":[{"name":"McGill University and Jewish General Hospital Montreal, Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[{"name":"University of Calgary Calgary, Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar628"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.05.011"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.005"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.01.013"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780351014"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.12.001"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2614"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3495"},{"key":"e_1_2_8_10_1","first-page":"S12","article-title":"Anti\u2010PM\u2010Scl antibody in patients with systemic sclerosis","volume":"30","author":"Koschik RW","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar147"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb05291.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.4.941"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1729"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199211000-00001"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.02.031"},{"key":"e_1_2_8_17_1","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements P","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_8_18_1","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy EC","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21583"},{"key":"e_1_2_8_20_1","first-page":"458","article-title":"Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right\u2010heart catheterization","volume":"35","author":"Hsu VM","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_21_1","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"Medsger TA","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_8_22_1","first-page":"S42","article-title":"Assessment of disease severity and prognosis","volume":"21","author":"Medsger TA","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/rheum.111133"},{"key":"e_1_2_8_24_1","first-page":"1528","article-title":"Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA","volume":"34","author":"Santiago M","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2012.03.001"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.07.005"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108616"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38428","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:32:27Z","timestamp":1759941147000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,27]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1002\/art.38428"],"URL":"https:\/\/doi.org\/10.1002\/art.38428","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,27]]}}}